Japan's Daiichi Sankyo has agreed a deal to buy Ambit Biosciences of the US for up to $410 million, bringing a new leukaemia candidate into its pipeline. The $15-per-share cash deal - which could ...

It is a TROP2 directed antibody drug conjugate (ADC) designed using Daiichi Sankyo’s proprietary DXd ADC technology, ...

Seattle’s claim against Daiichi Sankyo covers all of the Japanese firm’s antibody-drug conjugate (ADC) pipeline following the alliance between 2008 and 2015. Daiichi paid $4 billion to gain ...

Enhertu’s approval in additional indications, Dato-DXd, and pipeline assets could continue to drive future growth. After Enhertu, Dato-DXd, and HER3-DXd, Daiichi Sankyo’s other ADCs are still ...

AstraZeneca is set to report its third-quarter 2024 earnings Tuesday morning. The company's Q2 performance suggests strong ...

The first patients have been dosed in three global, randomized phase 3 trials evaluating the efficacy and safety of datopotamab deruxtecan (Dato-DXd)- ...

The drugmaker emphasized plans to move further away from singular reliance on Keytruda while reporting solid sales growth in ...

Designed using Daiichi Sankyo's proprietary DXd ADC Technology, datopotamab deruxtecan is one of six DXd ADCs in the oncology pipeline of Daiichi Sankyo, and one of the most advanced programmes in ...

It covers the pipeline drug profiles ... Merck Sharp & Dohme LLC, Daiichi Sankyo Company, Inspirna, Lyell Immunopharma, Genentech, Cantargia AB, Arcus Biosciences, Inc., Neogap Therapeutics ...

Total Worldwide Sales Were $16.7 Billion, an Increase of 4% From Third Quarter 2023; Excluding the Impact of Foreign Exchange ...